Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + cyclophosphamide + dexamethasone followed by thalidomide + prednisone in newly diagnosed Waldenström macroglobulinemia
ChiCTR-OIC-16008402Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of thalidomide, cyclophosphamide, dexamethasone and prednisone in Lymphoplasmacytic Lymphoma (LPL) and Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: overall response rate. Started May 2016; status: recruiting.
02
Drugs
thalidomidecyclophosphamidedexamethasoneprednisone
03
Conditions
Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ChiCTR-OIC-16008402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008402.